BIOM BIOMOLECULAR LIFE HOLDINGS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1091326 · Fiscal year ends 12/31
Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY51.4%
TTM EPS YoY91.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-381.4%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets431.7%
Debt / equity—
Current ratio0.01x
Interest coverage-1.32x
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-305.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2015Q32015-09-30 | 2015Q22015-06-30 | 2015Q12015-03-31 | 2014Q4*2014-12-31 | 2014Q32014-09-30 | 2014Q22014-06-30 | 2014Q12014-03-31 | 2013Q4*2013-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $140,151 | $162,790 | $159,648 | -$110,162 | $339,881 | $224,377 | $411,606 | $458,881 |
| SG&A expense | $118,712 | $127,060 | $138,469 | $180,853 | $64,637 | $296,245 | $369,620 | $1.27M |
| Operating income | -$644,446 | -$739,266 | -$801,480 | -$541,450 | -$798,772 | -$1.15M | -$1.65M | -$2.13M |
| Interest expense | $250,200 | $431,763 | $714,749 | $666,246 | $687,800 | $554,092 | $851,813 | $573,030 |
| Net income | -$1.01M | -$1.40M | -$1.46M | -$424,500 | -$1.06M | -$2.00M | -$2.70M | -$3.08M |
| EBITDA | — | — | — | -$541,450 | -$798,772 | — | — | -$2.13M |
| EPS (basic) | -0.01 | -0.02 | -0.03 | — | -0.04 | -0.09 | -0.14 | — |
| EPS (diluted) | -0.01 | -0.02 | -0.03 | — | -0.04 | -0.09 | -0.14 | — |
| Weighted avg. shares (diluted) | 85.45M | 66.90M | 51.64M | — | 28.94M | 22.78M | 18.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22,919 | $4,335 | $30,066 | $33,992 | $53,842 | $32,852 | $148,666 | $713,892 |
| Current assets | $40,326 | $39,413 | $92,081 | $246,266 | $60,463 | — | — | $789,386 |
| PP&E, net | $0 | $0 | $0 | $0 | $0 | — | — | $0 |
| Intangibles | $1.08M | $1.08M | $1.08M | $1.08M | $1.08M | — | — | $1.08M |
| Total assets | $1.12M | $1.12M | $1.17M | $1.32M | $1.14M | — | — | $1.87M |
| Current liabilities | $5.46M | $5.96M | $5.89M | $5.83M | $6.31M | — | — | $6.33M |
| Total liabilities | $4.82M | $5.31M | $5.24M | $5.16M | $5.63M | — | — | $5.64M |
| Shareholders' equity | -$4.34M | -$4.84M | -$4.73M | -$4.51M | -$5.17M | — | — | -$4.47M |
| Shares outstanding | 101.50M | 77.31M | 61.45M | 46.22M | 31.23M | — | — | 17.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$48,321 | -$237,561 | -$165,042 | -$407,412 | -$468,342 | -$308,934 | -$724,771 | -$539,803 |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$407,412 | — | — | — | -$539,803 |
| Investing cash flow | — | — | — | $0 | — | — | — | $0 |
| Financing cash flow | $66,905 | $211,830 | $161,116 | $387,562 | $489,332 | $193,120 | $159,545 | $1.24M |
| Depreciation & amortization | — | — | — | $0 | $0 | — | — | $0 |
| Stock-based compensation | $62,752 | $85,507 | $91,548 | $0 | -$590,480 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.